OncoTarget® Myeloid68
An NGS-Based Test for Myeloid Leukemia
Available in 6-7 business days
FDA-Cleared (510k) test
Clear insights to therapy options
What is OncoTarget® Myeloid68?
Next-Generation sequencing (NGS) performs massively parallel sequencing of genomes, allowing for the analysis of a significant number of genomic targets with a single test. Critically, NGS allows for the detection of aberrations that may only be present at very low levels, but which may have important clinical relevance for the patient’s diagnosis and prognosis.

GoPath’s MyeloidNGS68 Panel provides actionable information for improved diagnosis, prognosis, and risk stratification for myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).
Clinical Values
of OncoTarget® Myeloid68
Myeloid Leukemia Cells
Myeloid 68 detected
Assay performnce for detection of the Myeloid panel variants
Ref Lab Variants
GoPath Variants
Additional testing available
Three different tests to determine cancer risk – PROSTATENOW™ – Germline test for prostate cancer, BRCANOW® – Hereditary test for breast and ovarian cancer -LYNCHNOW® – Screening to detect lynch syndrome.
Testing for a diagnosis, therapy and monitoring of certain blood disorders including leukemia and lymphoma.
GoPath® Labs
Whether a patient is in remission or is currently undergoing treatment, the sooner cancer recurrence or metastasis is found, the sooner the patient can receive appropriate therapy and treatment.
Delivering the broadest, FDA-cleared Comprehensive Genomic Profiling for solid tumors.
Begin your journey- our team is ready to get you started.